Claire E. Dearden, MD, Highlights the Pharmacotherapeutic Strategies for the Management of B- and T-cell PLL

Article

Claire E. Dearden, MD, Consultant Hematologist, Head of CLL Clinic, Royal Marsden Hospital, London, UK, highlights the pharmacotherapeutic strategies for the management of B- and T-cell PLL, noting the clinical outcomes associated with the diseases, and briefly touches on the future of PLL therapy.

Claire E. Dearden, MD, Consultant Hematologist, Head of CLL Clinic, Royal Marsden Hospital, London, UK, highlights the pharmacotherapeutic strategies for the management of B- and T-cell PLL, noting the clinical outcomes associated with the diseases, and briefly touches on the future of PLL therapy.

This video was taken on Saturday, December 8, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Related Content
© 2025 MJH Life Sciences

All rights reserved.